Poplar Therapeutics Launches With $50M Series A to Advance a New Class of Anti-IgE Therapy for Multiple Atopic Conditions

Poplar Therapeutics成立，获得5000万美元A轮融资，用于推进针对多种特应性疾病的新型抗IgE疗法。

Phase 1 clinical trial underway for PHB-050, a next-generation IgE depleter, with data expected in 2H26

PHB-050（一种新一代IgE清除剂）的1期临床试验正在进行中，预计2H26获得数据。

Series A financing led by SR One, Vida Ventures, and Platanus

由SR One、Vida Ventures和Platanus领投的A轮融资

Poplar to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 11:00AM PT

Poplar 将于 1 月 15 日星期四上午 11:00（太平洋时间）在第 44 届摩根大通年度医疗保健会议上发表演讲。

BOSTON, January 7, 2026-- Poplar Therapeutics, Inc. announced its launch today highlighting its $50 million Series A financing led by SR One, Vida Ventures and Platanus. Previously known as Phylaxis Bioscience, Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions..

波士顿，2026年1月7日——Poplar Therapeutics公司今天宣布启动，并强调其由SR One、Vida Ventures和Platanus领投的5000万美元A轮融资。该公司前身为Phylaxis Bioscience，是一家临床阶段的免疫学公司，正在开发一类新型抗IgE疗法，用于治疗食物过敏及其他特应性疾病。

“We are launching Poplar Therapeutics with the goal of transforming the treatment of atopic diseases. PHB-050 has the potential to be best-in-class and help millions of patients in need of effective treatment options,” said Chip Baird, chief executive officer of Poplar Therapeutics. “The ongoing Phase 1 will provide important data on safety, pharmacokinetics and PHB-050's potential to rapidly drive IgE levels toward zero.

“我们成立波普勒治疗公司，目标是转变过敏性疾病的治疗方法。PHB-050有潜力成为同类最佳药物，帮助数百万需要有效治疗选择的患者，”波普勒治疗公司首席执行官奇普·贝尔德表示。“正在进行的第一阶段试验将提供关于安全性、药代动力学以及PHB-050迅速降低IgE水平至接近零的潜力的重要数据。”

We expect to have the results of our Phase 1 study during the second half of 2026.”.

我们预计将在2026年下半年获得第一阶段研究的结果。

Despite the availability of omalizumab (Xolair®), a first-generation anti-IgE therapy, millions of patients with atopic diseases such as food allergy, allergic asthma and atopic dermatitis lack effective treatment options, representing a significant unmet medical need. Patients with elevated IgE levels are ineligible for or do not adequately respond to currently available treatments..

尽管已有第一代抗IgE疗法奥马珠单抗（Xolair®），但数百万患有特应性疾病（如食物过敏、过敏性哮喘和特应性皮炎）的患者仍缺乏有效的治疗选择，这代表了一个显著未满足的医疗需求。IgE水平升高的患者要么不符合现有治疗的条件，要么对现有治疗无法充分响应。

“We have incorporated the last 20 years of learnings from the field into the design of PHB-050,” said Tony Yao, M.D., Ph.D., founder of Poplar Therapeutics. “Preclinical data suggest PHB-050 can not only bind and block soluble IgE but can also rapidly drive total IgE toward zero. With PHB-050, our goal is to enable the effective treatment of all patients, including those with highly elevated IgE levels who cannot be treated with existing therapies.”.

“我们已经将过去20年从该领域获得的经验融入到PHB-050的设计中，”Poplar Therapeutics创始人Tony Yao医学博士说道。“临床前数据表明，PHB-050不仅能够结合并阻断可溶性IgE，还可以迅速将总IgE降至接近零。通过PHB-050，我们的目标是实现对所有患者的高效治疗，包括那些现有疗法无法治疗的IgE水平极高的患者。”

Mr. Baird was appointed president and CEO of Poplar Therapeutics in October 2025 and brings over 20 years of executive operating experience leading highly innovative, patient-focused companies. Most recently, Mr. Baird served as CEO of 2seventy bio, leading through its successful sale to Bristol Myers Squibb.

贝尔德先生于2025年10月被任命为Poplar Therapeutics的总裁兼首席执行官，他拥有超过20年领导高度创新、以患者为中心的公司的高管运营经验。最近，贝尔德先生担任2seventy bio的首席执行官，成功带领公司出售给百时美施贵宝。

The Poplar leadership team also includes René van der Merwe, M.D., as chief medical officer and Vicki Eatwell as chief financial officer. Prior to joining Poplar, Dr. van der Merwe previously held leadership roles at Aiolos Bio and DBV Technologies. Ms. Eatwell most recently served as CFO of 2seventy bio..

Poplar的领导团队还包括雷内·范德梅尔韦（René van der Merwe）博士担任首席医疗官，以及维基·伊特韦尔（Vicki Eatwell）担任首席财务官。在加入Poplar之前，范德梅尔韦博士曾担任Aiolos Bio和DBV Technologies的领导职务。伊特韦尔女士最近曾担任2seventy bio的首席财务官。

Poplar's Board of Directors brings deep experience across all aspects of drug discovery, drug development and operations:

Poplar的董事会在药物发现、药物开发和运营等各个方面都带来了深厚的经验：

• Dan Welch (Board Chair), former CEO of InterMune, experienced Board member

• Dan Welch（董事会主席），InterMune前首席执行官，经验丰富的董事会成员

• Joanne Waldstreicher, M.D., former CMO, Johnson & Johnson

• 乔安妮·瓦尔德斯特雷彻，医学博士，前强生公司首席医疗官

• Jill Carroll, Partner, SR One

• 吉尔·卡罗尔，合伙人，SR One

• Helen Kim, Senior Managing Director, Vida Ventures

• 海伦·金，高级董事总经理，维达创投

• Tony Yao, M.D., Ph.D., Founder and Chief Scientific Officer

• 姚东，医学博士，哲学博士，创始人兼首席科学官

• Chip Baird, President and CEO, Poplar Therapeutics

• Chip Baird，总裁兼首席执行官，Poplar Therapeutics

Poplar Therapeutics will be presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15 at 11:00am PT.

Poplar Therapeutics 将于 1 月 15 日星期四上午 11:00（太平洋时间）在旧金山举行的第 44 届摩根大通医疗保健会议上发表演讲。

About PHB-050

关于 PHB-050

More than seven million patients with atopic conditions have high IgE levels, with approximately three million considered ineligible for or resistant to current standard therapies. In food allergy, approximately 50% of patients are classified as having high IgE levels.

超过七百万名特应性疾病患者的IgE水平较高，其中约三百万名患者被认为不符合当前标准治疗的条件或对当前标准治疗产生耐药性。在食物过敏方面，大约50%的患者被归类为具有高IgE水平。

PHB-050 is a novel, next-generation anti-IgE antibody designed to treat multiple atopic diseases, including food allergy, asthma and atopic dermatitis with potential application for select orphan immunology and inflammatory diseases. Its unique triple-action mechanism is designed to not only block IgE from binding to mast cells that trigger allergic reactions, but also to rapidly reduce circulating IgE and inhibit its production..

PHB-050 是一种新型的下一代抗 IgE 抗体，旨在治疗多种特应性疾病，包括食物过敏、哮喘和特应性皮炎，并有可能应用于某些罕见免疫学和炎症性疾病。其独特的三重作用机制不仅能够阻止 IgE 与引发过敏反应的肥大细胞结合，还能够快速减少循环中的 IgE 并抑制其生成。

About Poplar Therapeutics

关于Poplar Therapeutics

Poplar Therapeutics, Inc. is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in treating allergic disorders, which was incorporated in 2024. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a unique triple-action design currently being studied in atopic diseases.

Poplar Therapeutics, Inc. 是一家临床阶段的免疫学公司，致力于开发新型抗 IgE 疗法，以挑战过敏性疾病治疗的传统方法，该公司成立于 2024 年。其主导项目 PHB-050 是一种下一代抗 IgE 抗体，具有独特的三重作用机制，目前正针对特应性疾病进行研究。

Poplar is pursuing the bold idea that IgE can be rapidly driven toward zero, with the goal of helping people with IgE-mediated conditions move from fear toward freedom..

Poplar 正在追求一个大胆的想法，即可以将 IgE 迅速降至接近零，旨在帮助 IgE 介导疾病的患者从恐惧走向自由。

Contact:

联系：

Media Contact:

媒体联系人：

Terri Clevenger

特丽·克利文格

tclevenger@waterhousebrands.com

tclevenger@waterhousebrands.com